|
DE19608753C1
(de)
*
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
EP1623017B1
(en)
*
|
2003-05-08 |
2010-09-15 |
Life Technologies Corporation |
Generation and isolation of antigen-specific t cells
|
|
US20070032570A1
(en)
*
|
2003-11-11 |
2007-02-08 |
Canon Kabushiki Kaisha |
Ink comprising a block copolymer dispersing agent having a hydrophilic and a hydrophobic segment and an ink-applying process and apparatus using the same
|
|
US20050281786A1
(en)
*
|
2004-06-18 |
2005-12-22 |
David Poulsen |
AAV mediated gene delivery to cochlear cells
|
|
US20100080784A1
(en)
*
|
2008-09-12 |
2010-04-01 |
Torrey Pines Institute For Molecular Studies |
Methods for treating cachexia and lymphopenia
|
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
SG11201608862SA
(en)
|
2014-04-23 |
2016-11-29 |
Juno Therapeutics Inc |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
|
ES2959683T3
(es)
|
2014-07-15 |
2024-02-27 |
Juno Therapeutics Inc |
Células manipuladas para terapia celular adoptiva
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
JP7057669B2
(ja)
|
2014-10-20 |
2022-04-20 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法において投薬するための方法および組成物
|
|
PL3215601T3
(pl)
|
2014-11-05 |
2020-11-02 |
Juno Therapeutics, Inc. |
Sposoby transdukcji i przetwarzania komórek
|
|
ES2987087T3
(es)
|
2014-12-03 |
2024-11-13 |
Juno Therapeutics Inc |
Métodos y composiciones para terapia celular adoptiva
|
|
JP6865688B2
(ja)
|
2015-01-16 |
2021-04-28 |
ジュノー セラピューティクス インコーポレイテッド |
Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
CN108174607A
(zh)
|
2015-05-29 |
2018-06-15 |
朱诺治疗学股份有限公司 |
用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
|
CN108779466B
(zh)
|
2015-11-30 |
2024-03-29 |
杜克大学 |
用于通过基因编辑修正人肌营养不良蛋白基因的治疗靶标和使用方法
|
|
EP4212547A1
(en)
|
2015-12-03 |
2023-07-19 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
|
MA43378A
(fr)
|
2015-12-03 |
2018-10-10 |
Juno Therapeutics Inc |
Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
|
|
US11815514B2
(en)
|
2015-12-04 |
2023-11-14 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
US20190287013A1
(en)
|
2016-03-16 |
2019-09-19 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
|
EP3430549A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
|
CA3018588A1
(en)
|
2016-03-22 |
2017-09-28 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
|
WO2017180915A2
(en)
|
2016-04-13 |
2017-10-19 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
IL262772B2
(en)
|
2016-05-06 |
2023-10-01 |
Juno Therapeutics Inc |
Genetically engineered cells and methods of making the same
|
|
JP2019517518A
(ja)
|
2016-06-03 |
2019-06-24 |
メモリアル スローン ケタリング キャンサー センター |
早期治療選択肢としての養子細胞療法
|
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
|
WO2018005559A1
(en)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
|
WO2018017754A1
(en)
|
2016-07-19 |
2018-01-25 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
WO2018023100A2
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies and related methods
|
|
CN110087672A
(zh)
|
2016-07-29 |
2019-08-02 |
朱诺治疗学股份有限公司 |
免疫调节多肽及相关组合物和方法
|
|
AU2017322752A1
(en)
|
2016-09-12 |
2019-03-21 |
Juno Therapeutics, Inc. |
Perfusion bioreactor bag assemblies
|
|
JP2019529565A
(ja)
|
2016-09-28 |
2019-10-17 |
アトッサ・ジェネティックス・インコーポレイテッド |
養子細胞治療の方法
|
|
MA46354A
(fr)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics Inc |
Molécules se liant spécifiquement au vph
|
|
MA46649A
(fr)
|
2016-10-13 |
2019-08-21 |
Juno Therapeutics Inc |
Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
|
|
WO2018093591A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
|
CN110139669A
(zh)
|
2016-11-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
T细胞疗法和btk抑制剂的组合疗法
|
|
EP3548622A1
(en)
|
2016-12-02 |
2019-10-09 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
|
AU2017368331A1
(en)
|
2016-12-03 |
2019-06-13 |
Acerta Pharma B.V. |
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
|
WO2018102786A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
|
CN110290807B
(zh)
|
2016-12-03 |
2024-06-14 |
朱诺治疗学股份有限公司 |
确定car-t细胞给药的方法
|
|
JP2020505034A
(ja)
|
2017-01-20 |
2020-02-20 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞表面コンジュゲートならびに関連する細胞組成物および方法
|
|
KR20190116420A
(ko)
|
2017-02-17 |
2019-10-14 |
프레드 헛친슨 켄서 리서치 센터 |
Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
|
|
EP3585402B1
(en)
|
2017-02-27 |
2024-03-06 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
|
BR112019019005A2
(pt)
|
2017-03-14 |
2020-04-14 |
Sara Elizabeth Church |
métodos para armazenagem criogênica
|
|
JOP20180027A1
(ar)
|
2017-03-28 |
2019-01-30 |
Cell Design Labs Inc |
بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
|
|
US20230190796A1
(en)
|
2017-04-07 |
2023-06-22 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
|
AU2018251188A1
(en)
|
2017-04-14 |
2019-10-31 |
Juno Therapeutics, Inc. |
Methods for assessing cell surface glycosylation
|
|
WO2018197949A1
(en)
|
2017-04-27 |
2018-11-01 |
Juno Therapeutics Gmbh |
Oligomeric particle reagents and methods of use thereof
|
|
SG11201910143TA
(en)
|
2017-05-01 |
2019-11-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and an immunomodulatory compound
|
|
US11413310B2
(en)
|
2017-06-02 |
2022-08-16 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
US11740231B2
(en)
|
2017-06-02 |
2023-08-29 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
|
CN114058590B
(zh)
|
2017-06-20 |
2024-08-06 |
居里研究所 |
Suv39h1缺陷的免疫细胞
|
|
JP2020526194A
(ja)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
免疫療法薬と関連する毒性を評価するためのマウスモデル
|
|
MX2020000900A
(es)
|
2017-07-29 |
2021-01-08 |
Juno Therapeutics Inc |
Reactivos para expandir celulas que expresan receptores recombinantes.
|
|
WO2019032929A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR PREPARING GENETICALLY MODIFIED CELLS
|
|
MA49979A
(fr)
|
2017-08-09 |
2020-06-17 |
Juno Therapeutics Inc |
Procédés de production de compositions de cellules génétiquement modifiées et compositions associées
|
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
|
WO2019051335A1
(en)
|
2017-09-07 |
2019-03-14 |
Juno Therapeutics, Inc. |
METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY
|
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
TW201932482A
(zh)
|
2017-11-01 |
2019-08-16 |
美商奇諾治療有限公司 |
對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸
|
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
|
CN111615556A
(zh)
|
2017-11-01 |
2020-09-01 |
朱诺治疗学股份有限公司 |
产生t细胞组合物的方法
|
|
MX2020004240A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Proceso para generar composiciones terapeuticas de celulas modificadas.
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
AU2018358250B2
(en)
|
2017-11-01 |
2025-06-05 |
Editas Medicine, Inc. |
Methods, compositions and components for CRISPR-CAS9 editing of TGFBR2 in T cells for immunotherapy
|
|
CN111886012A
(zh)
|
2017-11-06 |
2020-11-03 |
朱诺治疗学股份有限公司 |
细胞疗法与γ分泌酶抑制剂的组合
|
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン，インコーポレイテッド |
免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
|
|
US20200330983A1
(en)
|
2017-11-10 |
2020-10-22 |
Juno Therapeutics, Inc. |
Closed-system cryogenic vessels
|
|
KR20200116081A
(ko)
|
2017-12-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포의 투약 및 조절 방법
|
|
MX2020005908A
(es)
|
2017-12-08 |
2020-10-07 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t modificadas.
|
|
KR102862251B1
(ko)
|
2017-12-08 |
2025-09-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법을 위한 표현형 마커 및 관련 방법
|
|
AU2018379091A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
CN112204048A
(zh)
|
2017-12-15 |
2021-01-08 |
朱诺治疗学股份有限公司 |
抗cct5结合分子及其使用方法
|
|
WO2019126358A1
(en)
|
2017-12-22 |
2019-06-27 |
Cell Design Labs, Inc. |
Single- and multi-chain chimeric antigen receptors
|
|
US12509492B2
(en)
|
2018-01-19 |
2025-12-30 |
Duke University |
Genome engineering with CRISPR-Cas systems in eukaryotes
|
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
US12280119B2
(en)
|
2018-03-23 |
2025-04-22 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
MX2020010459A
(es)
|
2018-04-05 |
2021-01-20 |
Juno Therapeutics Inc |
Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas.
|
|
KR20210020873A
(ko)
|
2018-04-05 |
2021-02-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
|
|
TWI840351B
(zh)
|
2018-04-05 |
2024-05-01 |
美商奇諾治療有限公司 |
T細胞受體及表現其之工程化細胞
|
|
CN112584902A
(zh)
|
2018-05-03 |
2021-03-30 |
朱诺治疗学股份有限公司 |
嵌合抗原受体（car）t细胞疗法和激酶抑制剂的组合疗法
|
|
WO2019246563A1
(en)
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
US20210230671A1
(en)
|
2018-08-09 |
2021-07-29 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
|
EP3833742A2
(en)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
|
MA53612A
(fr)
|
2018-09-11 |
2021-09-15 |
Juno Therapeutics Inc |
Procédés d'analyse par spectrométrie de masse de compositions cellulaires modifiées
|
|
CA3115298A1
(en)
|
2018-10-12 |
2020-04-16 |
Theradaptive, Inc. |
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
|
|
MX2021005013A
(es)
|
2018-10-31 |
2021-07-21 |
Juno Therapeutics Gmbh |
Métodos para la selección y estimulación de células y aparatos para los mismos.
|
|
SG11202104188VA
(en)
|
2018-11-01 |
2021-05-28 |
Juno Therapeutics Inc |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
BR112021007626A2
(pt)
|
2018-11-01 |
2021-10-13 |
Juno Therapeutics, Inc. |
Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
|
|
BR112021008738A2
(pt)
|
2018-11-06 |
2021-11-03 |
Juno Therapeutics Inc |
Processo para produzir células t geneticamente construídas
|
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
|
SG11202105084VA
(en)
|
2018-11-16 |
2021-06-29 |
Juno Therapeutics Inc |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
FI3886875T3
(fi)
|
2018-11-30 |
2024-07-23 |
Juno Therapeutics Inc |
Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
|
|
CN113692285A
(zh)
|
2018-11-30 |
2021-11-23 |
朱诺治疗学股份有限公司 |
在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
|
|
MX2021009087A
(es)
|
2019-01-29 |
2021-09-08 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
|
|
BR112021021075A2
(pt)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
|
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
|
CN114207136A
(zh)
|
2019-06-07 |
2022-03-18 |
朱诺治疗学股份有限公司 |
自动化t细胞培养
|
|
MX2021015317A
(es)
|
2019-06-12 |
2022-03-11 |
Juno Therapeutics Inc |
Terapia de combinacion de una terapia citotoxica mediada por celulas y un inhibidor de una proteina de la familia bcl2 de prosupervivencia.
|
|
KR20250095757A
(ko)
|
2019-06-21 |
2025-06-26 |
카이트 파마 인코포레이티드 |
TGF-β 수용체 및 이의 사용 방법
|
|
US20220251572A1
(en)
|
2019-07-23 |
2022-08-11 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
|
|
JP7770306B2
(ja)
|
2019-08-30 |
2025-11-14 |
ジュノー セラピューティクス インコーポレイテッド |
細胞を分類するための機械学習方法
|
|
CA3152525A1
(en)
|
2019-09-03 |
2021-03-11 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
|
US20220372516A1
(en)
|
2019-10-11 |
2022-11-24 |
Takara Bio Inc. |
siRNA EXPRESSION VECTOR
|
|
CA3159380A1
(en)
|
2019-10-30 |
2021-05-06 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
|
EP4055383A1
(en)
|
2019-11-05 |
2022-09-14 |
Juno Therapeutics, Inc. |
Methods of determining attributes of therapeutic t cell compositions
|
|
AU2020379043A1
(en)
|
2019-11-07 |
2022-06-02 |
Juno Therapeutics, Inc. |
Combination of a T cell therapy and (S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
|
|
JP7605840B2
(ja)
|
2019-12-06 |
2024-12-24 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞性悪性疾患を処置するための細胞療法と関連する毒性および奏効に関係する方法
|
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
|
BR112022010627A2
(pt)
|
2019-12-06 |
2022-08-16 |
Juno Therapeutics Inc |
Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados
|
|
US20230071910A1
(en)
|
2020-01-24 |
2023-03-09 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
|
CA3170153A1
(en)
|
2020-02-12 |
2021-08-19 |
Juno Therapeutics, Inc. |
Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
|
JP2023519098A
(ja)
|
2020-02-12 |
2023-05-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃｄ１９指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
|
|
CN115916223A
(zh)
|
2020-04-10 |
2023-04-04 |
朱诺治疗学股份有限公司 |
与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
|
|
CN115916239A
(zh)
|
2020-04-15 |
2023-04-04 |
治疗调适公司 |
用于靶向治疗性递送至骨的组合物和方法
|
|
CA3181399A1
(en)
|
2020-04-28 |
2021-11-04 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
EP4150640A1
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
|
US20230181641A1
(en)
|
2020-05-13 |
2023-06-15 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
KR20230042283A
(ko)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
|
|
CN116490518A
(zh)
|
2020-07-17 |
2023-07-25 |
西穆尔克斯股份有限公司 |
用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
|
|
WO2022023576A1
(en)
|
2020-07-30 |
2022-02-03 |
Institut Curie |
Immune cells defective for socs1
|
|
KR20230095918A
(ko)
|
2020-08-05 |
2023-06-29 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
|
|
US20230303665A1
(en)
|
2020-08-28 |
2023-09-28 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
IL301955A
(en)
|
2020-10-07 |
2023-06-01 |
Asklepios Biopharmaceutical Inc |
Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
JP2024503027A
(ja)
|
2021-01-11 |
2024-01-24 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ８標的ウイルスベクターの使用方法
|
|
CN117693508A
(zh)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
T细胞疗法和dgk抑制剂的组合
|
|
WO2022204070A1
(en)
|
2021-03-22 |
2022-09-29 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
IL307262A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY
|
|
MX2023011370A
(es)
|
2021-03-29 |
2023-11-24 |
Juno Therapeutics Inc |
Combinacion de una terapia con celulas t con receptores de antigenos quimericos (car) y un compuesto inmunomodulador para el tratamiento de linfoma.
|
|
CA3214683A1
(en)
|
2021-04-16 |
2022-10-20 |
Julie Ann RYTLEWSKI |
Combination therapies with bcma-directed t cell therapy
|
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
|
US20250304915A1
(en)
|
2021-05-25 |
2025-10-02 |
Institut Curie |
Myeloid Cells Overexpressing BCL2
|
|
CA3227105A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
JP2025501272A
(ja)
|
2021-12-28 |
2025-01-17 |
ムネモ・セラピューティクス |
不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20250154503A1
(en)
|
2022-01-14 |
2025-05-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
US20250152709A1
(en)
|
2022-02-01 |
2025-05-15 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
AU2023223404A1
(en)
|
2022-02-22 |
2024-08-29 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2023201133A1
(en)
|
2022-04-14 |
2023-10-19 |
Board Of Regents Of The University Of Nebraska |
Cell therapy for alzheimer's disease
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
EP4543923A1
(en)
|
2022-06-22 |
2025-04-30 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
US20250382640A1
(en)
|
2022-06-29 |
2025-12-18 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
KR20250047766A
(ko)
|
2022-08-05 |
2025-04-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
|
|
WO2024040254A2
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
KR20250084921A
(ko)
|
2022-08-26 |
2025-06-11 |
주노 쎄러퓨티크스 인코퍼레이티드 |
델타-유사 리간드 3 (dll3)에 특이적인 항체 및 키메라 항원 수용체
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
CN120239746A
(zh)
|
2022-09-19 |
2025-07-01 |
图恩疗法股份有限公司 |
用于调节t细胞功能的组合物、系统和方法
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
EP4611798A1
(en)
|
2022-11-02 |
2025-09-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024124132A1
(en)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Machine learning methods for predicting cell phenotype using holographic imaging
|
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
US20240285762A1
(en)
|
2023-02-28 |
2024-08-29 |
Juno Therapeutics, Inc. |
Cell therapy for treating systemic autoimmune diseases
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025059362A1
(en)
|
2023-09-13 |
2025-03-20 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025076472A1
(en)
|
2023-10-06 |
2025-04-10 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2026008700A1
(en)
|
2024-07-03 |
2026-01-08 |
Immunofusion Bv |
Il7r alpha signalling domain, chimeric antigen receptor and uses thereof
|